Sinjard 25 mg (Tablet)
Unit Price: ৳ 50.00 (2 x 7: ৳ 700.00)
Strip Price: ৳ 350.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Empagliflozin |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Adjunct to diet and exercise for type 2 diabetes
- Reduction of cardiovascular death risk in type 2 diabetes with established cardiovascular disease
Pharmacology
Sodium glucose co-transporter-2 (SGLT-2) inhibition leading to reduced renal glucose reabsorption and increased glucose excretion, contributing to reduced hyperglycemia, weight loss, and reduced blood pressure
Dosage & Administration
- Recommended dose of 10 mg once daily
- Can be increased to 25 mg once daily in tolerant patients
- Recommended to take in the morning with or without food
- Correction of volume depletion before initiation recommended
Interaction
- Increased urine volume with diuretics
- Risk of hypoglycemia with insulin or insulin secretagogues
- Positive urine glucose test due to increased urinary glucose excretion
- Unreliable 1,5-anhydroglucitol (1,5-AG) assay for glycemic control in patients taking SGLT2 inhibitors
Contraindications
Hypersensitivity reaction to Empagliflozin or its ingredients, severe renal impairment, end-stage renal disease, dialysis
Side Effects
- Urinary tract infections
- Female genital mycotic infections
- Dehydration
- Hypotension
- Weakness
- Dizziness
- Increased thirstiness
Pregnancy & Lactation
- Use during pregnancy if potential benefit justifies potential risk to fetus
- Not recommended during breastfeeding due to unknown excretion in human milk
Precautions & Warnings
- Assessment of renal function recommended before initiation
- Not to be initiated in patients with eGFR less than 45 ml/min/1.73 m²
- No dose adjustment needed for eGFR greater than or equal to 45 ml/min/1.73 m²
Overdose Effects
Supportive measures recommended in case of overdose, hemodialysis not studied for removal
Therapeutic Class
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
Keep in a cool & dry place (below 30°C), protected from light & moisture, keep out of the reach of children
Chemical Structure
- Molecular Formula: C23H27ClO7
- Chemical Structure Image: https://medex.com.bd/storage/res/g-res-1275-empagliflozin-chemical-structure-Z3X0mrA6UvgM682Jgp8K.svg
Common Questions about Sinjard 25 mg Tablet
- SGLT-2 inhibitor reducing glucose reabsorption from the kidney
- Used to improve glycemic control in adults
- May be unsafe to use during pregnancy
- Probably unsafe to use during breastfeeding
- Should be used cautiously in patients with underlying kidney disease
- No dose adjustment needed for patients with mild to moderate liver disease
- Quick tips for usage and monitoring